Dynogen Pharmaceuticals, Inc.
Company Information
Waltham, MA
United States
Phone: 1 781 839 5100
Fax: 1 781 839 5200
Overview
Dynogen is a biopharmaceutical company developing more effective drugs for gastrointestinal (GI) and genitourinary (GU) disorders, including irritable bowel syndrome (IBS) and overactive bladder (OAB). We focus on compounds that have previously been in the clinic and therefore have known safety and pharmacokinetic profiles. This approach, combined with the experience of the Dynogen team, enables our programs to be prioritized for near-term commercial potential, reduces the risk involved in clinical development, and has allowed Dynogen to rapidly build a high value development stage pipeline. Today, we have three products in development for four indications: - DDP733 for the treatment of irritable bowel syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (n-GERD); - DDP225 for the treatment of irritable bowel syndrome with diarrhea (IBS-d); and
Corporate Structure
CHIEF EXECUTIVE OFFICER
TOP EXECUTIVES
Mark P Carthy General Partner, Oxford Bioscience Partners
Michael F. Bigham Board of Directors
Augustine Lawlor General Partner, Healthcare Ventures, Llc
Gerald F Gebhart Board of Directors
Robert C Lorette Chief Business Officer and Senior Vice President
Kate Bingham Managing Partner, Sv Life Sciences
Nadia M J Rupniak Senior Director, Technology Transfer
Steven B Landau Board of Directors
Ted T Ashburn Senior Director, Business Development
Tony Scullion
Michael W Spellman Senior Vice President, Pharmaceutical Development
William C de Groat Board of Directors
J David Leander Board of Directors
Karl B Thor Chief Scientific Officer and Director
William D Steers Professor and Chairman of Urology
Scott Holmes Corporate Controller
Suhail Nurbhai Vice President for Clinical Development
Michael Camilleri Board of Directors
Heather Savelle Manager, Corporate Communications
Mark F Boshar Vice President, Legal Affairs and Chief Patent Counsel
